TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02400944

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: The study questionnaires (baseline and 2 follow-ups) will capture information on how modifiable factors, including the patients' smoking habits and body weight, have changed since last contact. RSA will conduct this interview at a time convenient to the patient either during a scheduled clinic visit or by telephone.

Intervention type: OTHER
Intervention: Saliva and/or urine sample
Description: Patients will contribute approximately 5 mL of saliva at baseline, and at the time of their follow-up questionnaires. If the patient declines to contribute a saliva specimen, they can contribute approximately 10mL of urine. Urine is routinely collected from bladder cancer patients for clinically-related tests. We will also collect urine from every participant for whom the sample is not depleted by clinical tests at the end of the day. Saliva/urine specimens will be tested for cotinine which is regarded as the gold standard to detect recent smoking exposure and is widely used to identify active smokers in epidemiologic studies.
Study: NCT02796508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Non-action video game training
Description: PSI2013-41409R. Effects of video game training on behavioral and neuroimaging measures of attention and memory

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Non-cognitive video game training
Description: 16 training sessions with The Sims over 8-10 weeks in small groups
Study: NCT04773990

Intervention type: DEVICE
Group type: OTHER
Intervention: Biodex Balance System
Description: Subjects will receive several unique training modules using biodex
Study: NCT03755986

Intervention type: DEVICE
Group type: OTHER
Intervention: ATOMO Diagnostic Test
Description: The ATOMO diagnostic test device is the only intervention used in this study.
Study: NCT02982967

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Activity
Description: Recreational Physical Activity (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
Study: NCT04773990

Intervention type: OTHER
Group type: OTHER
Intervention: specific physical therapy exercise program
Description: Subjects will receive recommended PT program

Intervention type: OTHER
Group type: OTHER
Intervention: specific physical therapy exercise program
Description: Subjects will receive recommended PT program
Study: NCT01370759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleaning capsule
Description: Capsules containing the tested materials aimed to improve colon cleansing
Study: NCT00439452

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine-Based Collaborative Care
Description: Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Practice Based Collaborative Care
Description: One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
Study: NCT01176565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous nicardipine hydrochloride
Description: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.~Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous nicardipine hydrochloride
Description: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.~Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present.
Study: NCT02878044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thyroid Decision Aid
Description: The Thyroid Decision Aid is a tool designed to help clinicians and patients discuss treatment options for thyroid nodules.
Study: NCT01737294

Intervention type: DRUG
Intervention: Qutenza exposure
Description: Cutaneous patch
Study: NCT02488460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physically active math lessons
Description: The intervention consists of a nine month period with physical activity as part of, and integrated, in math lessons
Study: NCT02017522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 11C-PBR PET
Description: Subjects will have a positron emission tomography (PET) CT scan using 11C-PBR28 as a radiotracer. This study will evaluate inflammation due to cardiac sarcoidosis. The CT scan will improve the images. The total scan time will be about 30 minutes. There will also be some time required for prep, such as inserting an intravenous (IV) catheter in an arm or forearm. Including prep time, the scan will take approximately two hours.~Subjects will also undergo a cardiac MRI. Cardiac MRI uses strong magnetic fields to make pictures of the heart. We will use gadolinium containing contrast material, given through an intravenous (IV) catheter to highlight areas of scar in your heart which may be due to cardiac sarcoidosis. This scan will take about 60 minutes.
Study: NCT02559414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study: NCT01062061

Intervention type: BIOLOGICAL
Intervention: VARIVAX™
Description: Attenuated live varicella vaccine
Study: NCT03435562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL electronic cigarette
Description: Effects of JUUL electronic cigarette use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IQOS electronic cigarette
Description: Effects of IQOS electronic cigarette use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own Brand cigarette
Description: Effects of own brand cigarette use.
Study: NCT01131741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: This group receives 3 mL of 1% lidocaine containing epinephrine IV during operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: This group receives 3 mL of saline IV during operation.
Study: NCT01373320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay health advisor interactions
Description: For smoking cessation: Cooper-Clayton group sessions plus motivational interviewing, both delivered by local lay health advisor.~For all cancer screenings: lay health advisor home visits incorporating motivational interviewing and focused on decreasing participant-identified barriers to screening.
Study: NCT00764257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PREVELLE Shape

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Study: NCT03462953

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gingival tissue samples will be harvested
Description: Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls and during periodontal surgery or extraction of hopeless teeth with periodontal disease ..~The dissected gingival samples will be washed in saline solution and fixed in 4% buffered formalin for 48 hours, dehydrated in ascending grades of ethyl alcohol, cleared in xylene and embedded in paraffin and will be subjected to the following:.~1. Sections of 4-5 µm in thickness will be obtained, deparaffinized, rehydrated and subjected to histological staining and histomorphometric analysis.~2. Real time- PCR for TGF-B1 ,Vimenten , E-Cadherin .
Study: NCT03327311

Intervention type: DEVICE
Intervention: Bellafill
Description: Bellafill injected into site of pre-planned surgery (i.e., mini-abdominoplasty or redundant abdominal tissue removal) at two depths (dermis \& deep dermis).
Study: NCT03385278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rTMS
Description: 20HZ Repetitive Transcranial Magnetic Stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rTMS
Description: 20HZ Repetitive Transcranial Magnetic Stimulation
Study: NCT00581867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: 40IU insulin aspart applied intranasally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03974737

Intervention type: DEVICE
Intervention: CRI device (non-invasive vitals sign measurement)
Description: Survey administration, Orthostatic vital measurements

Intervention type: DEVICE
Intervention: CRI device (non-invasive vitals sign measurement)
Description: Survey administration, Orthostatic vital measurements

Intervention type: DEVICE
Intervention: CRI device (non-invasive vitals sign measurement)
Description: Survey administration, Orthostatic vital measurements
Study: NCT03631277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photo-activated oral disinfection
Description: Application of PAD solution using disposable tip with agitation of the solution for 60 seconds using a brush; Placement of the light disposable tip in center of lesion and holding it just above the surface; Activation of the red light for 60 seconds; (h)Sealing the cavity with glass ionomer and then filling with composite resin as a final restoration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: calcium hydroxide( Dycal ® Dentsply Caulk )was applied using calcium hydroxide applicator followed by glass ionomer and then composite resin as a final restoration
Study: NCT03409510

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVB radiation
Description: UVB treatment regimen:~Week 1-2: 0.85 kilo Joule/m2 twice per week Week 3-7: 0.85 kilo Joule/m2 three times per week Week 8-9: 1.4 kilo Joule/m2 three times per week
Study: NCT03002311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epharmix/CareSignal eHealth
Description: The self-scheduling text and phone messaging system was built by Epharmix/CareSignal. Participants in the intervention group began receiving text or voice messages (for landlines) starting 1 hour following ED discharge if during normal business hours, or at 1000 the next business morning. Automated messages were sent up to 3 days in a row or until the participant responded or opted out. The phone system would ultimately connect them directly to their referral provider or clinic to schedule an appointment. Once participants hung up with the referral clinic, the intervention texted or called back to solicit the appointment date. If a date was entered, the system sent reminders at 14 days, 7 days, 3 days, and 1 day before the appointment. After the appointment, the intervention texted or called participants to confirm if they attended.
Study: NCT03327311

Intervention type: DEVICE
Intervention: Bellafill
Description: Bellafill injected into site of pre-planned surgery (i.e., mini-abdominoplasty or redundant abdominal tissue removal) at two depths (dermis \& deep dermis).

Intervention type: DEVICE
Intervention: Bellafill
Description: Bellafill injected into site of pre-planned surgery (i.e., mini-abdominoplasty or redundant abdominal tissue removal) at two depths (dermis \& deep dermis).

Intervention type: DEVICE
Intervention: Bellafill
Description: Bellafill injected into site of pre-planned surgery (i.e., mini-abdominoplasty or redundant abdominal tissue removal) at two depths (dermis \& deep dermis).
Study: NCT02522091

Intervention type: DEVICE
Group type: OTHER
Intervention: functional brain MRI

Intervention type: DEVICE
Group type: OTHER
Intervention: functional brain MRI
Study: NCT01513681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine Tablets 200 mg
Study: NCT00939276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)
Description: One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac ophthalmic suspension vehicle
Description: One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
Study: NCT00343200

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viagra (sildenafil citrate)
Description: Sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 12 weeks (8-week DB phase and 4-week OL phase).
Study: NCT03667560

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dermacell ADM without basement membrane
Description: Patient will be implanted with Dermacell ADM.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FlexHD
Description: Patient will be implanted with FlexHD.
Study: NCT04484233

Intervention type: DEVICE
Intervention: iAnemia Decision Support System
Description: iAnemia permits to display the appropriate guideline using several inputs about a patient: age, type and delay of the surgery, gender, hemoglobin level, and iron deficiency status.
Study: NCT00058604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous injection of EBV specific CTLs
Description: Each patient will receive injections of 2x10e7 , 5x10e7 , or 10e8 CTLs/m2 via IV injection. 6 weeks = 1 course
Study: NCT02397421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Sodium Glucose Linked Transporter Type 2 (SGLT-2) Inhibitor
Study: NCT02522091

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychology tests

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychology tests

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychology tests
Study: NCT01513681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine Tablets 200 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal®
Description: Lamictal® 200 mg Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamictal®
Description: Lamictal® 200 mg Tablets
Study: NCT06319040

Intervention type: OTHER
Intervention: Fall risk test
Description: Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk

Intervention type: OTHER
Intervention: Tegner Activity Level
Description: Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.

Intervention type: OTHER
Intervention: Tegner Activity Level
Description: Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.

Intervention type: OTHER
Intervention: Tegner Activity Level
Description: Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.

Intervention type: OTHER
Intervention: Lysholm Knee Scoring Scale
Description: Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.

Intervention type: OTHER
Intervention: Lysholm Knee Scoring Scale
Description: Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.

Intervention type: OTHER
Intervention: Lysholm Knee Scoring Scale
Description: Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.
Study: NCT03656744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801
Description: HTD1801 tablets, 250mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801
Description: HTD1801 tablets, 250mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets manufactured to mimic HTD1801 tablets
Study: NCT00396565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER OROS paliperidone
Description: Type= exact number, unit= mg, number= 3, form= tablet, route= oral use. Two tablets once daily for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form= tablet, route= oral use. Two tablets once daily for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Type= exact number, unit= mg, number= 2.5, form= tablet, route= oral use. Four tablets once daily for 6 weeks.
Study: NCT03900052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haptic cane
Description: • A haptic biofeedback cane was designed and manufactured to measure the user applied axial cane load, compare the load to the targeted 20% BW threshold, and then deliver a vibrotactile feedback in the cane handle when the loading was greater than threshold. The cane data acquisition was temporally synchronized to the motion analysis system and recorded axial cane loads at 100 Hz for later analysis. The haptic biofeedback cane consisted of a conventional bariatric walking cane (Patterson Medical Ltd) with a loadcell (Digi-Key100 LBS. Load Cell) placed inside a 3D printed modular cane foot. A microcontroller (Sparkfun™ Pro Micro), SD disk storage (Sparkfun™ OpenLog), eccentric rotating mass vibration motor (model 306-109, Precision Microdrives Limited), USB communications port, and battery completed the system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haptic cane
Description: • A haptic biofeedback cane was designed and manufactured to measure the user applied axial cane load, compare the load to the targeted 20% BW threshold, and then deliver a vibrotactile feedback in the cane handle when the loading was greater than threshold. The cane data acquisition was temporally synchronized to the motion analysis system and recorded axial cane loads at 100 Hz for later analysis. The haptic biofeedback cane consisted of a conventional bariatric walking cane (Patterson Medical Ltd) with a loadcell (Digi-Key100 LBS. Load Cell) placed inside a 3D printed modular cane foot. A microcontroller (Sparkfun™ Pro Micro), SD disk storage (Sparkfun™ OpenLog), eccentric rotating mass vibration motor (model 306-109, Precision Microdrives Limited), USB communications port, and battery completed the system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: typical cane
Description: Typical training cane loading training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: typical cane
Description: Typical training cane loading training
Study: NCT04356794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture needle with electrical stimulation
Description: EA is treated for 4 weeks, 3 times per week.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: Sham EA is treated for 4 weeks, 3 times per week.
Study: NCT01556321

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will receive placebo (soy oil; 757 mg/capsule, 3 capsules with each breakfast, lunch and dinner) in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will receive placebo (soy oil; 757 mg/capsule, 3 capsules with each breakfast, lunch and dinner) in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
Study: NCT04317079

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxytyrosol
Description: Administration of hydroxytyrosol in doses 15mg and 5 mg compared to placebo for 6 months
Study: NCT01556321

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ]
Description: Subjects will receive green tea (757 mg/capsule \[84.5 mg EGCG + 2.1 mg caffeine \], 3 capsules with each breakfast, lunch and dinner)in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ]
Description: Subjects will receive green tea (757 mg/capsule \[84.5 mg EGCG + 2.1 mg caffeine \], 3 capsules with each breakfast, lunch and dinner)in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.